Imaging Subgroup Formed Under NCI/FDA Oncology Task Force
This article was originally published in The Gray Sheet
Executive Summary
FDA and the National Cancer Institute plan to explore the use of imaging technologies to improve oncology drug development
You may also be interested in...
McClellan’s FDA Legacy? Decisive Role In Product Development Priorities
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress
Imaging Technologies Tagged For FDA Drug Development Initiative
FDA is commencing an initiative to encourage use of imaging technologies to develop surrogate endpoints for drug submissions
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.